Punch Biopsy Required for Superficial Basal Cell Carcinoma

Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

Real-World Study Supports Use of DermaSensor in Primary Care to Differentiate Cancerous and Benign Lesions

Your daily dose of the clinical news you may have missed.

September 23rd 2024

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

The AI-based point-of-care device outperformed clinician standard of care for sensitivity (90% vs 40%) and had a negative predictive value of 98.9%

Related Content

Ryan Flinn

October 25th 2024

Lebrikizumab Demonstrates Sustained Disease Control in Atopic Dermatitis Up to 3 Years

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.

Roflumilast Cream 0.15% Leads to Consistent Improvements in Atopic Dermatitis Across Diverse Skin Types

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

FDA Accepts NDA for Delgocitinib Cream, Developed Specifically to Treat Chronic Hand Eczema

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

FDA Approves Lebrikizumab-lbkz for Moderate to Severe AD: Daily Dose

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

Real-World Study Supports Use of DermaSensor in Primary Care to Differentiate Cancerous and Benign Lesions

Your daily dose of the clinical news you may have missed.

September 23rd 2024